193 related articles for article (PubMed ID: 19108890)
1. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Jin J; Chen H; Cao L
Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
[No Abstract] [Full Text] [Related]
2. [Imatinib. An anticancer agents indicated in the treatment of chronic myeloid leukemia]].
Taéron C
Rev Infirm; 2004 Feb; (98):39-40. PubMed ID: 15042992
[No Abstract] [Full Text] [Related]
3. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
[No Abstract] [Full Text] [Related]
4. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
[No Abstract] [Full Text] [Related]
5. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Richardson MW; Grewal SS
Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
[No Abstract] [Full Text] [Related]
6. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Uchiyama M; Ikeda T
Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
[No Abstract] [Full Text] [Related]
7. An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy.
Maeda T; Mutoh T; Muta H; Nakayama M; Nakajima Y; Ikuta T; Yasuda M; Etoh T; Shimizu K; Nakazaki Y; Hiroyama T; Somada S; Kurita R; Tani K; Shiratsuchi M; Nishimura J
J Am Geriatr Soc; 2004 Oct; 52(10):1783-4. PubMed ID: 15450069
[No Abstract] [Full Text] [Related]
8. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
[No Abstract] [Full Text] [Related]
9. [Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies].
Yagasaki F
Nihon Rinsho; 2007 Jan; 65 Suppl 1():505-10. PubMed ID: 17474456
[No Abstract] [Full Text] [Related]
10. Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
Anthony N; Shanks J; Terebelo H
Leuk Res; 2010 Sep; 34(9):1250-1. PubMed ID: 20646761
[No Abstract] [Full Text] [Related]
11. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
Champlin RE; Kantarjian H
Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
[No Abstract] [Full Text] [Related]
12. Imatinib in chronic myeloid leukemia.
Krause SW; Holler E
N Engl J Med; 2007 Apr; 356(17):1780; author reply 1780. PubMed ID: 17460235
[No Abstract] [Full Text] [Related]
13. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
14. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
[No Abstract] [Full Text] [Related]
15. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
16. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Tefferi A; Kantarjian H
Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
[No Abstract] [Full Text] [Related]
17. [Treatment of chronic myeloid leukemia with imatinib].
Ohnishi K
Gan To Kagaku Ryoho; 2011 May; 38(5):746-8. PubMed ID: 21702117
[No Abstract] [Full Text] [Related]
18. The best frontline therapy for CML: imatinib?
Saglio G
Clin Adv Hematol Oncol; 2010 Apr; 8(4):240-2. PubMed ID: 20505646
[No Abstract] [Full Text] [Related]
19. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
[No Abstract] [Full Text] [Related]
20. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
Dvorak P; Hruba M; Subrt I
Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
[No Abstract] [Full Text] [Related]
[Next] [New Search]
